Top Story

FDA grants orphan drug status to eye drop treatment for keratoconus

November 15, 2017

The FDA granted orphan drug designation to IVMED-80, an eye drop used for cross-linking the cornea to treat keratoconus.

“Receiving orphan drug designation is an important regulatory milestone, and we are pleased that IVMED-80 for keratoconus has been granted this status,” Gerald Simmons, CEO of iVeena Delivery Systems, said in a press release from the company. “We are developing IVMED-80 to offer another option in the treatment of keratoconus. The prospect of treating keratoconus with only a daily eye drop is very attractive, and our team is committed to advancing the clinical development.”

Massachusetts ODs continue to seek glaucoma privileges

November 8, 2017
The Massachusetts Society of Optometrists is working with practitioners, residents and state legislators to ensure its optometric scope of practice is in line with the…
In the Journals

Silicone hydrogels, autologous serum effective for persistent epithelial defects

November 6, 2017
The combined use of silicone hydrogel contact lenses with autologous serum eye drops can treat postinfectious corneal persistent epithelial defects and prevent…
FDA NewsPerspective

FDA approves Bausch + Lomb glaucoma drop

November 3, 2017
The FDA has approved the new drug application for the once-daily glaucoma treatment Vyzulta, according to a press release issued jointly by Bausch + Lomb, a subsidiary…
More Headlines »

Ocular Surface Diseases, Disorders, and Dysfunctions™: Volume 3, Number 2

This activity is supported by an educational grant from Shire.

Ocular surface disease (OSD) is a group of disorders commonly seen in ophthalmic practice, but it is challenging to…
More »
Meeting News

VIDEO: New device helps patients create natural tears

September 15, 2017
More »
Resource Centers
American Academy of Optometry

American Academy of Optometry

Meeting News

VIDEO: Débridement - First step in treating herpes simplex keratitis

March 6, 2017
More »